Slide 1: Real-World Innovation - Earnings Call Q3 2025
evOgene | ‘REAL-WORLD INNOVATION 1 03.2025 S OFER HAVIV | PRESIDENT & CEO November 20, 2025
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT evOgene This presentation contains “forward-looking statements’ relating to future events, and Evogene Ltd. (the "Company", may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters rega
Slide 3: Earnings Call Q3 2025 Agenda
EARNINGS CALL 03 2025 AGENDA CEO UPDATE - By Ofer Haviv CFO UPDATE - By Yaron Eldad Q&A 3 evOgene
Slide 4: CEO Update: Financial & Business Highlights
4 CEO UPDATE FINANCIAL & BUSINESS HIGHLIGHTS During the first nine months ending September 30, 2025, Evogene advanced its strategic transition toward establishing itself as a leader in computational chemistry, with a focus on the generative design of small molecules for the pharmaceutical and agricu
Slide 5: CEO Update: Financial & Business Highlights
5 CEO UPDATE FINANCIAL & BUSINESS HIGHLIGHTS Total Research and Development expenses in the nine months ending September 30, 2025 were approximately $6.2 million, compared to approximately $9.8 million in the same period of 2024. The decrease is primarily attributable to a reduction in Biomica’s exp
Slide 6: CEO Update: Subsidiaries & Related Parties
6 CEO UPDATE FINANCIAL & BUSINESS HIGHLIGHTS Subsidiaries & related parties: Lavie Bio — Transfer of team and majority or activity to ICL, completed; collaboration agreement with existing partner continues; advancement of funds distribution to Lavie Bio’s shareholders, with Evogene as the majority h
Slide 7: Evogene Pioneers Real-World Innovation
EVOGENE PIONEERS REAL-WORLD INNOVATION Using a proprietary generative Al engine, we design highly potent and novel small molecules, optimized across multiple- parameters, for the pharmaceutical and ag-chemical industries
Slide 8: There Is a Gap Between Real-World Challenges and Innovative Solutions
a 4 ~ OF THERE IS A GAP BETWEEN REAL-WORLD CHALLENGES AND INNOVATIVE SOLUTIONS 8 evOgene
Slide 9: Utilizing AI and Advanced Proprietary Algorithms
UTILIZING Al AND ADVANCED PROPRIETARY ALGORITHMS §@._, TO DELIVER INNOVATIVE SMALL MOLECULES, & w TAILORED TO REAL-WORLD COMMERCIAL A v a PRODUCT NEEDS > ~ @ 9 evOgene
Slide 10: We Call It: Real-World Innovation
WE CALL IT: REAL-WORLD INNOVATION evOgene
Slide 11: Our Story in Sentences
OUR STORY IN 3 SENTENCES GEN Al ENGINE REVOLUTIONIZING AG PIONEERING IN PHARMA Design of small molecules with Proven results with Differentiated tech offering that high probability of success J \ strategic collaborations y] \ fits market demand 1 evOgene
Slide 12: The Discovery & Optimization Challenge
THE DISCOVERY & OPTIMIZATION CHALLENGE DESIGN THE RIGHT CANDIDATES TO REACH THE MARKET SS I | DISCOVERY & OPTIMIZATION TARGET SELECTION —_ OOo FRY ADVANCED ‘APPROVED (protein) HIT HITTOLEAD LEAD DEVELOPMENT DEVELOPMENT PRODUCT IDENTIFICATION OPTIMIZATION PHARMA =| = PRECLINICAL «= |-—CLINCAL evOgene
Slide 13: Less Than 10% of Molecules Tested in Clinical Trials Make It to Market
LESS THAN 10% OF MOLECULES TESTED IN CLINICAL TRIALS MAKE IT TO MARKET B EVOGENE sasiou Discovery & optimization are the critical stages for increasing market success probability
Slide 14: The Multi-Parameter Optimization Challenge
THE MULTI-PARAMETER OPTIMIZATION CHALLENGE a Chemica Say ‘Molecular Welght Creating a molecule that will succeed through all development phases requires balancing in advance multiple, often competing, parameters Metabolic Stability THE CHALLENGE FOR TRADITIONAL METHODS: Optimization typically limite
Slide 15: Introducing ChemPass AI
INTRODUCING CHEMPASS Al: A MULTI-PARAMETER DESIGN ENGINE FOR REAL-WORLD INNOVATION ~evOgene Chem Pass MULTI-PARAMETER OPTIMIZATION Optimizes multiple-parameters simultaneously, adapted to project specific chemical, biological, and physical constraints, increasing probability of success NOVEL MOLECUL
Slide 16: ChemPass AI: Multi-Parameter Generative Design Engine
CHEMPASS Al: A MULTI-PARAMETER GENERATIVE DESIGN ENGINE FOR REAL-WORLD INNOVATION CHEMPASS Al TRANSFORMS TRADITIONAL METHODS: Optimization of diverse product specific parameters Lipophilicity (Log) Addresses multiple constraints ML Models (QSAR) simultaneously Minimizes lengthy, resource-intensive i
Slide 17: a
5 a evOgene
Slide 18: AgPlenus: A Growing Market with Plenty of Room for Innovation
*4gPlenus EVOGENE'S SUBSIDIARY A GROWING MARKET A WITH PLENTY OF ROOM FOR INNOVATION $43.3B 4 HERBICIDES! 1 Increase in pest resistance & regulatory requirements $22.2B FUNGICIDES FOR y] Urgent need for new CLRID LSE Modes of Action (MoAs) 3 Decreased rate in discovery $22.3B of new pesticides due t
Slide 19: Computational Chemistry Can Create Real-World Impact in Agriculture
Slide 20: AgPlenus Strategic Collaborations
“4gPlenus EVOGENE’S SUBSIDIARY 2 STRATEGIC COLLABORATIONS B A, BAYER — R "Bringing together AgPlenus' expertise with Bayer’s CropKey approach to crop protection innovation will help accelerate the delivery of essential, sustainable, and affordable solutions to farmers and set a new benchmark in the
Slide 21: AgPlenus: APTF-4 Internal Pipeline
*4gPlenus EVOGENE’S SUBSIDIARY APTF-4 PRESENTS STRONG POTENTIAL INTERNAL PIPELINE FOR REAL-WORLD INNOVATION WHEAT BLOTCH ra DISRUPTING A $1.2B PROBLEM AT RECORD SPEED * 70% of EU fungicide usage in wheat is for Wheat Blotcht * EU market alone >$1.2B annually! * Widespread resistance to current top p
Slide 22: Our Story in Sentences: Pioneering in Pharma
OUR STORY IN 3 SENTENCES PIONEERING IN PHARMA Differentiated tech offering that y] \ fits market demand /\ /\ a n evOgene
Slide 23: Pharma Division: Growing Opportunity in AI-Drug Discovery
PHARMA DIVISION GROWING OPPORTUNITY IN Al-DRUG DISCOVERY SM. ALL Account for Al-based candidates in pipeline Discovery market expected to reach 58% >60 $190.68B MOLECULES Of total pharmaceutical market ($1,344B) 150% CAGR in last 3 years by 2034 a ; B CVOGENE varvaw cna 9 seme oret 9 rao sh
Slide 24: Pharma Division: The Discovery and Optimization Challenge
PHARMA DIVISION THE DISCOVERY AND OPTIMIZATION CHALLENGE DEVELOPING CANDIDATES THAT WILL REACH THE MARKET TARGET SELECTION DISCOVERY & OPTIMIZATION PRE-CLINICAL PHASE | (protein) PHASE Il PHASE Ill APPROVED Trial PRODUCT QVOGENE tsps gover
Slide 25: ChemPass AI: Driving Higher Cumulative Probability of Success
B PHARMA DIVISION CHEMPASS Al: DRIVING HIGHER CUMULATIVE PROBABILITY OF SUCCESS ‘CANDIDATE CUMULATIVE PROBABILITY OF SUCCESS. oan >—f { | f barr NISCOVER 2 OF TSLEATION PRE-CLINICAL PHASE PHASE! PHASE I APPROVED Trial PRODUCT EVOGENE tcrimestiinrnresrsorsra
Slide 26: Pharma Division: Business Strategy
PHARMA DIVISION BUSINESS STRATEGY CAPTURE THE VALUE OF CHEMPASS Al through diverse collaborative partnerships to accelerate small molecule-based drug development. PARTNERING WITH PHARMA AND BIOTECH COMPANIES that complement our technology, enabling groundbreaking innovations that benefit both partie
Slide 27: Pharma Division: Strategic Collaborations
PHARMA DIVISION STRATEGIC COLLABORATIONS Evogene and Professor Ehud Gazit 600 of Tel Aviv University Collaborate to TeLavv OOTIN develop new therapeutics for UNIVERSITY 2/N'7N metabolite Disease The collaboration aims to design novel small molecules that can Scanning electron microscopy of crystals
Slide 28: Delivering Real-World Innovation for Two Strategic Markets
DELIVERING REAL-WORLD INNOVATION FOR TWO STRATEGIC MARKETS THROUGH COLLABORATIONS & INTERNAL ACTIVITY EXTERNAL COLLABORATIONS: 00 Metabolic Disease PHARMA DIVISION INTERNAL PIPELINE Undisclosed Chem P a SS = ‘STRATEGIC COLLABORATION CD Herbicides € CORTEVA Herbicides *4gPlenus EVOGENE'S SUBSIDIARY I
Slide 29: Earnings Call Q3 2025 Agenda
EARNINGS CALL 03 2025 AGENDA CEO UPDATE - By Ofer Haviv CFO UPDATE - By Yaron Eldad Q&A » evOgene
Slide 30: CFO Update: Statements of Financial Position
CFO UPDATE FINANCIAL HIGHLIGHTS so ~evOgene CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION US. dollars in thousands ASSETS (CURRENT ASSETS: Cash and cash equivalents Shogt-term bank deposits Trade receivables Other receivables and prepaid expenses Deferred expenses related to issuance of warr
Slide 31: CFO Update: Liabilities and Equity
CFO UPDATE ‘September 30, December 31. FINANCIAL HIGHLIGHTS ms am Unaudited Lansiuerzs AND EQUrTy ase Trade payables Employees and payroll accruals Lease liabilities Liabilities in respect of government grants Deferred revenues and other advances ‘Warrants and pre-funded warrants liability Convertib
Slide 32: Consolidated Interim Statements of Profit or Loss
CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS - dollars in thousands (except share and per share amounts) CFO UPDATE FINANCIAL HIGHLIGHTS es a Unaudited ‘Audited Revenues S353 $ 403 $312 S40 $5577 Cost of revenues 1810 1,688 457 1082 2,380 Gross profit 1.29 2346 155 698 3197 Operating expenses R
Slide 33: Earnings Call Q3 2025 Agenda
EARNINGS CALL 03 2025 AGENDA CEO UPDATE - By Ofer Haviv CFO UPDATE - By Yaron Eldad Q&A % evOgene
Slide 34: Creating Real-World Innovation for a Better Future - Thank You
Creating Hl REAL-WORLD 4 INNOVATION for a better future HANK YOU